openPR Logo
Press release

Global Rituximab biosimilar market is expected to grow at rapid pace with strong presence of major players such as Amgen, AryoGen Pharmed, BioXpress Therapeutics, Boehringer Ingelheim, Celltrion, Teva Pharmaceutical, Intas Biopharmaceuticals, JHL Biotech,

02-10-2019 06:43 PM CET | Health & Medicine

Press release from: InsightAce Analytic Pvt. Ltd.

InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on ' Global Rituximab Biosimilar Market Assessment – Revenue Forecast, Clinical Trial/Pipeline Analysis, Brand/Originator Drug Historic Revenue and Forecast Till 2026'

Request for ToC/Proposal: https://bit.ly/2SoYrjn

Rituximab is a chimeric anti-CD20 antibody that binds to the CD20 antigen present on the normal and malignant B cells surface. It is indicated for the treatment of blood cancer (CD20-positive) such as chronic lymphocytic leukemia and non-Hodgkin’s lymphoma as well as autoimmune disorder such as Rheumatoid arthritis. Rituximab is marketed under the trade name of MabThera in Europe and rest of World, except Japan by Roche. In the United States it marketed as Rituxan by Genentech in partnership with Biogen Idec. In Japan it is marketed by Chugai and Zenyaku Kogyo Co. Ltd. It is approved in the U.S. in 1997 and by European Medical Agency in June 1998. Rituximab is one of the top selling pharmaceutical product of Roche Holding AG. Therefor many biosimilar pharmaceutical companies are focusing on product development of rituximab biosimilar to compel the biosimilar product market share.
The rituximab biosimilar market is expected to grow at higher pace during forecast period,since the rituximab is one of the best seller drug product that accounts for around 2.1 million prescriptions worldwide since the market launch. In addition, rituximab has lost its patent in the United States and Europe in 2016 and 2013 respectively.

The Rituximab biosimilar market is fragmented/consolidated with presence of many/few players that operates in local as well as international market.
Global Rituximab biosimilar Market reports cover prominent players like Amgen, AryoGen Pharmed, BioXpress Therapeutics, Boehringer Ingelheim, Celltrion, Teva Pharmaceutical, Intas Biopharmaceuticals, JHL Biotech, mAbxience SA., Mylan, Pfizer, Sandoz, Zenotech Laboratories and many more.

Curious about this latest version of report?

Obtain Report Details @ https://bit.ly/2SoYrjn

Market Segments
• Global Rituximab biosimilar Market Outlook (Revenue, US$ Mn, 2017 - 2027) By Application
o Non-Hodgkin’s lymphoma,
o Chronic Lymhocytic Leukemia,
o Rheumatoid arthritis and others

• Global Rituximab Biosimilar Market Outlook (Revenue, US$ Mn, 2017 - 2027) By Distribution Channel
o Hospital Pharmacy
o Online Pharmacy
o Retail Pharmacy
o Other Direct Distribution Channels

Why should buy this report:
 To receive a comprehensive analysis of the prospects for global Rituximab biosimilar market
 To receive industry overview and future trends Rituximab biosimilar market
 To analyze the Rituximab biosimilar market drivers and challenges
 To get information on Rituximab biosimilar market size and forecast
 To get details on Rituximab biosimilar clinical trial/pipeline analysis
 Originator drug historic revenue
 Originator drug key news/industry activities
 Major Mergers & Acquisition in Rituximab biosimilar industry

For More Information @ https://bit.ly/2SoYrjn

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Email us: info@insightaceanalytic.com
Call us: +1 718 593 4405
Pune, Maharashtra 411004

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Rituximab biosimilar market is expected to grow at rapid pace with strong presence of major players such as Amgen, AryoGen Pharmed, BioXpress Therapeutics, Boehringer Ingelheim, Celltrion, Teva Pharmaceutical, Intas Biopharmaceuticals, JHL Biotech, here

News-ID: 1574737 • Views: 1144

More Releases from InsightAce Analytic Pvt. Ltd.

Global Continuous Glucose Monitoring (CGM) Sensors Market 2021 | Medtronics, Dex …
InsightAce Analytic Pvt. Ltd. features the release of the market research report on “Global Continuous Glucose Monitoring (CGM) Sensors Market Assessment – Industry Analysis, Competitive Analysis, COVID 19 Impact Analysis, and Revenue & Volume Forecast Till 2028” According to the latest research by InsightAce Analytic, the global continuous glucose monitoring (CGM) sensors market was valued at US$ 2,786.4 Mn in 2019 and it is expected to reach US$ 11,747.4 million
Global Agricultural Microbials Market 2021 | BASF SE , Bayer CropScience, Sumito …
InsightAce Analytic Pvt. Ltd. features the release of the market research report on “Global Agricultural Microbials Market Assessment – – Industry Analysis, Competitive Analysis, COVID 19 Impact Analysis, and Revenue Forecast Till 2030” According to the latest research by InsightAce Analytic, the global market was valued at US$ XX Mn in 2020 and it is expected to reach US$ XX million in 2030, recording a promising CAGR of XX% from
Global Longevity and Anti-Senescence Therapy Market 2021 | Acorda Therapeutics, …
InsightAce Analytic Pvt. Ltd. features the release of market research report on “Global Longevity and Anti-Senescence Therapy Market Assessment – Industry Analysis, Competitive Analysis, COVID 19 Impact Analysis, and Revenue Forecast Till 2028” According to the latest research by InsightAce Analytic, the global market expected to record a promising CAGR during the period of 2020-2028. Longevity and Anti-Senescence therapies are targeted at providing therapeutic options to combat the aging-related functional declines
Global Vaccine Cold Chain Logistics Market 2021 | Cryoport, DHL Express, GAC, Ly …
InsightAce Analytic Pvt. Ltd. announces the release of the market research report on “Global Vaccine Cold Chain Logistics Market Assessment – Industry Analysis, Competitive Analysis, COVID 19 Impact Analysis, and Revenue Forecast To2028” According to the latest research by InsightAce Analytic, the global market was valued at US$ XX Mn in 2020 and it is expected to reach US$ XX million in 2028, at a CAGR of XX% during the

All 5 Releases


More Releases for Rituximab

Rituximab Biosimilars Market Is Booming Worldwide (2020-2023) | By Top Leading P …
The Business Research Company offers "Rituximab Biosimilars Global Market Report 2020-30: COVID-19 Growth And Change" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country. It
Pemphigus Vulgaris Market 2026 Top Key Players are Principia Biopharma, Argenx S …
Pemphigus vulgaris is an autoimmune disorder in which painful blisters are formed on the mucus membrane and skin. The disorder is rare and affects mouth, nose, throat, lungs, eyes, and sometimes genitals. The disorder is caused when the body produces antibodies against self-cells, although the exact cause and mechanism is unknown. Formation of Immunoglobulin G (IgG) antibodies against self desmosomal adhesion proteins, present on epidermal keratinocytes, results in blister formation.
Global Rituximab Biosimilar Market 2027: Top Key Players Amgen Inc., Pfizer Inc. …
Rituximab is a chimeric anti-CD20 antibody that binds to the CD20 antigen present on the normal and malignant B cells surface. It is indicated for the treatment of blood cancer (CD20-positive) such as chronic lymphocytic leukemia and non-Hodgkin’s lymphoma as well as autoimmune disorder such as Rheumatoid arthritis. Rituximab is marketed under the trade name of MabThera in Europe and rest of World, except Japan by Roche. In the United
Rituxan (rituximab) Drug Market 2018-2023: Industry Share, Size, Statistics, App …
The report on Rituxan (rituximab) Drug market evaluates the growth trends of the industry through historical study 2013-2018 and estimates future prospects 2018-2023 based on comprehensive research. Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer. Over the next five years, RRI projects that Rituxan (rituximab) Drug will register a xx% CAGR in terms of revenue, reach US$ xx
CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023 Report
“CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023” report highlights: * Market Opportunity Assessment: More than US$ 60 Billion by 2023 * Clinical and Patent Insight on 17 Commercialize CD Antigen Drugs * Clinical and Licensing Insight on 184 CD Antigens in Clinical Pipeline * Dosage and Price Analysis on Key Drugs * Mechanism of CD Antigen Cancer Therapeutics * Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50
Feb 13, 2018: Rituximab Market In-Depth Progress Research 2018-2025
MarketsResearch.Biz Recently added detailed market study on the "Global Rituximab Market Research Report 2018-2025" which provides an outlook of current market value of Rituximab Market as well as the expected forecast of Rate on Investment (ROI) with growing CAGR of XX% in Rituximab Market by the end of 2025. The report on the global Rituximab market uses the top-down and bottom-up approaches to define, analyze, and describe the Rituximab market